View clinical trials related to Migraine Disorders.
Filter by:This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
The addition of clopidogrel on top of aspirin may reduce the occurrence of new-onset migraine headache episodes following transcatheter ASD closure.
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: - Subject self-examination skin irritation scores - Adverse events - Changes in vital signs and ECG parameters The secondary objective is to evaluate the long term efficacy of NP101 as assessed by: - Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101 - Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101 - Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101 - Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 - Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 - Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101 This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch). Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.
This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
The purpose of this study is to determine if there are significant differences in the side effects related to memory, repetition and recall among these three drugs when used in a pediatric population.
To assess CGRP levels in saliva through the evolution of migraine.
The purpose of this study is to compare the reduction in the number of severe headache days at six months in people with chronic migraine treated with topiramate and propranolol versus those treated with topiramate and a placebo.
This study will test the safety and how effective telcagepant is when taken with ibuprofen or acetaminophen in participants with migraine with or without aura. The primary study hypothesis is that at least one drug combination is superior to telecagepant alone in the treatment of acute migraines.